WO2007096251A1 - Inhibiteurs de cpt dans le système nerveux central en tant que médicaments antidiabétiques et/ou anti-obésité - Google Patents
Inhibiteurs de cpt dans le système nerveux central en tant que médicaments antidiabétiques et/ou anti-obésité Download PDFInfo
- Publication number
- WO2007096251A1 WO2007096251A1 PCT/EP2007/051197 EP2007051197W WO2007096251A1 WO 2007096251 A1 WO2007096251 A1 WO 2007096251A1 EP 2007051197 W EP2007051197 W EP 2007051197W WO 2007096251 A1 WO2007096251 A1 WO 2007096251A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- piperazine
- carboxyamide
- carboxamide
- trimethoxybenzyl
- methyl
- Prior art date
Links
- 210000003169 central nervous system Anatomy 0.000 title abstract description 5
- 239000003112 inhibitor Substances 0.000 title description 5
- 230000003178 anti-diabetic effect Effects 0.000 title description 2
- 239000000883 anti-obesity agent Substances 0.000 title description 2
- 239000003472 antidiabetic agent Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 83
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 claims abstract description 10
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 claims abstract description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 7
- 208000008589 Obesity Diseases 0.000 claims abstract description 6
- 235000020824 obesity Nutrition 0.000 claims abstract description 6
- 206010007559 Cardiac failure congestive Diseases 0.000 claims abstract description 5
- 206010019280 Heart failures Diseases 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 5
- 201000001421 hyperglycemia Diseases 0.000 claims abstract description 5
- 230000002265 prevention Effects 0.000 claims abstract description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 48
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- IACATHJLTBTMSC-UHFFFAOYSA-N (4-butylphenyl) carbamate Chemical compound CCCCC1=CC=C(OC(N)=O)C=C1 IACATHJLTBTMSC-UHFFFAOYSA-N 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- RJNJWHFSKNJCTB-UHFFFAOYSA-N benzylurea Chemical compound NC(=O)NCC1=CC=CC=C1 RJNJWHFSKNJCTB-UHFFFAOYSA-N 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 238000010586 diagram Methods 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- YYAMARKZHDKIHN-UHFFFAOYSA-N 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl n-(2-phenylethyl)carbamate Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCN(CCOC(=O)NCCC=2C=CC=CC=2)CC1 YYAMARKZHDKIHN-UHFFFAOYSA-N 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 125000001118 alkylidene group Chemical group 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 125000004417 unsaturated alkyl group Chemical group 0.000 claims description 2
- 229920002536 Scavenger resin Polymers 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 102100024853 Carnitine O-palmitoyltransferase 2, mitochondrial Human genes 0.000 abstract description 12
- 101000859570 Homo sapiens Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 abstract description 12
- 101000909313 Homo sapiens Carnitine O-palmitoyltransferase 2, mitochondrial Proteins 0.000 abstract description 12
- 101000989606 Homo sapiens Cholinephosphotransferase 1 Proteins 0.000 abstract description 12
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- UHWVSEOVJBQKBE-UHFFFAOYSA-N Trimetazidine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCNCC1 UHWVSEOVJBQKBE-UHFFFAOYSA-N 0.000 abstract description 7
- 230000002440 hepatic effect Effects 0.000 abstract description 4
- CYXKNKQEMFBLER-UHFFFAOYSA-N perhexiline Chemical compound C1CCCNC1CC(C1CCCCC1)C1CCCCC1 CYXKNKQEMFBLER-UHFFFAOYSA-N 0.000 abstract description 3
- 229960000989 perhexiline Drugs 0.000 abstract description 3
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract description 2
- 208000035475 disorder Diseases 0.000 abstract description 2
- 208000019622 heart disease Diseases 0.000 abstract description 2
- 229960001177 trimetazidine Drugs 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 54
- 230000015572 biosynthetic process Effects 0.000 description 50
- 238000003786 synthesis reaction Methods 0.000 description 50
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 42
- 238000004128 high performance liquid chromatography Methods 0.000 description 41
- 230000014759 maintenance of location Effects 0.000 description 41
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 28
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- 239000003480 eluent Substances 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 238000003760 magnetic stirring Methods 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- HACRKYQRZABURO-UHFFFAOYSA-N 2-phenylethyl isocyanate Chemical compound O=C=NCCC1=CC=CC=C1 HACRKYQRZABURO-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- ADAKRBAJFHTIEW-UHFFFAOYSA-N 1-chloro-4-isocyanatobenzene Chemical compound ClC1=CC=C(N=C=O)C=C1 ADAKRBAJFHTIEW-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 235000012631 food intake Nutrition 0.000 description 5
- 239000012948 isocyanate Substances 0.000 description 5
- 150000002513 isocyanates Chemical class 0.000 description 5
- 229920005990 polystyrene resin Polymers 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- QRBHVARIMDDOOV-UHFFFAOYSA-N 1-(isocyanatomethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CN=C=O)C=C1 QRBHVARIMDDOOV-UHFFFAOYSA-N 0.000 description 4
- FWPYUSLQCQDLJR-UHFFFAOYSA-N 1-ethyl-4-isocyanatobenzene Chemical compound CCC1=CC=C(N=C=O)C=C1 FWPYUSLQCQDLJR-UHFFFAOYSA-N 0.000 description 4
- KJMZSDMQWFWLCX-UHFFFAOYSA-N 1-heptoxy-4-isocyanatobenzene Chemical compound CCCCCCCOC1=CC=C(N=C=O)C=C1 KJMZSDMQWFWLCX-UHFFFAOYSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 210000003016 hypothalamus Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- TTXIFFYPVGWLSE-UHFFFAOYSA-N 1-[bis(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCNCC1 TTXIFFYPVGWLSE-UHFFFAOYSA-N 0.000 description 3
- GFNKTLQTQSALEJ-UHFFFAOYSA-N 1-isocyanato-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(N=C=O)C=C1 GFNKTLQTQSALEJ-UHFFFAOYSA-N 0.000 description 3
- OLBJNSPBWLCTOT-UHFFFAOYSA-N 2,4-dichloro-1-isocyanatobenzene Chemical compound ClC1=CC=C(N=C=O)C(Cl)=C1 OLBJNSPBWLCTOT-UHFFFAOYSA-N 0.000 description 3
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000000185 intracerebroventricular administration Methods 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- IQXXEPZFOOTTBA-UHFFFAOYSA-N 1-benzylpiperazine Chemical compound C=1C=CC=CC=1CN1CCNCC1 IQXXEPZFOOTTBA-UHFFFAOYSA-N 0.000 description 2
- LJJRXPXDTAUVQU-UHFFFAOYSA-N 1-butyl-4-isocyanatobenzene Chemical compound CCCCC1=CC=C(N=C=O)C=C1 LJJRXPXDTAUVQU-UHFFFAOYSA-N 0.000 description 2
- HHSIWJYERNCLKQ-UHFFFAOYSA-N 1-fluoro-4-(isocyanatomethyl)benzene Chemical compound FC1=CC=C(CN=C=O)C=C1 HHSIWJYERNCLKQ-UHFFFAOYSA-N 0.000 description 2
- QNKQBDZVEKZFBN-UHFFFAOYSA-N 1-isocyanato-4-methylsulfanylbenzene Chemical compound CSC1=CC=C(N=C=O)C=C1 QNKQBDZVEKZFBN-UHFFFAOYSA-N 0.000 description 2
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 230000004110 gluconeogenesis Effects 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- VUNXBQRNMNVUMV-UHFFFAOYSA-N phenyl(piperazin-1-yl)methanone Chemical compound C=1C=CC=CC=1C(=O)N1CCNCC1 VUNXBQRNMNVUMV-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- ZVFNUQWYLXXSJM-UHFFFAOYSA-N 1-ethyl-2-isocyanatobenzene Chemical compound CCC1=CC=CC=C1N=C=O ZVFNUQWYLXXSJM-UHFFFAOYSA-N 0.000 description 1
- DSVGFKBFFICWLZ-UHFFFAOYSA-N 1-fluoro-4-isocyanatobenzene Chemical compound FC1=CC=C(N=C=O)C=C1 DSVGFKBFFICWLZ-UHFFFAOYSA-N 0.000 description 1
- SGRGFGXMJYHVHW-UHFFFAOYSA-N 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethanamine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCN(CCN)CC1 SGRGFGXMJYHVHW-UHFFFAOYSA-N 0.000 description 1
- PCFSGQBTZGNFKL-UHFFFAOYSA-N 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethanol Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCN(CCO)CC1 PCFSGQBTZGNFKL-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- 240000008564 Boehmeria nivea Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- VYFLPFGUVGMBEP-UHFFFAOYSA-N Trimetazidine hydrochloride Chemical compound Cl.Cl.COC1=C(OC)C(OC)=CC=C1CN1CCNCC1 VYFLPFGUVGMBEP-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940067621 aminobutyrate Drugs 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 229940124345 antianginal agent Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- CBCIHIVRDWLAME-UHFFFAOYSA-N hexanitrodiphenylamine Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O CBCIHIVRDWLAME-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- YDNLNVZZTACNJX-UHFFFAOYSA-N isocyanatomethylbenzene Chemical compound O=C=NCC1=CC=CC=C1 YDNLNVZZTACNJX-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- MNBKLUUYKPBKDU-BBECNAHFSA-N palmitoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MNBKLUUYKPBKDU-BBECNAHFSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- ACNRTYKOPZDRCO-UHFFFAOYSA-N tert-butyl n-(2-oxoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC=O ACNRTYKOPZDRCO-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
Definitions
- the present invention describes a new class of compounds with inhibitory action on carnitine palmitoyl transferase (CPT) in the central nervous system (CNS). BACKGROUND OF THE INVENTION
- the object of the present invention therefore relates to new inhibitors of CPT1 , derivatives of trimetazidine and perhexiline, preferentially selective for the hepatic form of CPT1 (CPT1 L) also abundantly expressed in the brain, with different structural characteristics from those of the inhibitors which are the object of the earlier application WO99/59957.
- A is a monovalent group selected from the group comprising
- n is selected among 0, 1 , 2 and 3; R and R', the same or different, are selected from the group comprising H, alkyl
- R1 is selected between H and the group -CH 2 -CH(cycloalkyl (C 5 -C 6 )) 2
- X is selected between CH 2 and NR2;
- R2 is selected from the group comprising CH-(PhR3,R4,R5) 2 , -CH 2 PhR3,R4,R5, - COPhR3,R4,R5, - (CH 2 ) q -S-PhR3,R4,R5, -CH 2 COheterocyclo(C 5 -Ci 0 ), -
- Z is either absent or is selected from the group comprising CO, CH 2 ; r is selected between 0 and 1
- R3, R4 and R5, the same or different, are selected from the group including H, OH, halogen, alkoxy (CrC 4 ), straight or branched alkyl (CrC 4 ); or R3 and R4 together form an alkylidene(CrC 4 )-dioxy group;
- Y is selected between (CH 2 ) q -O and (CH 2 ) q NH; q is selected among 1 , 2 and 3; m is selected between 0 and 1 ; and its pharmaceutically acceptable salts.
- each of the products of formula (I) may exist both as a ramie mixture R/S and as separate isomeric forms
- the compounds of formula (I) can also be salified with pharmaceutically acceptable acids.
- Preferred pharmaceutically acceptable salts of the compounds of formula (I) according to the present invention are, for example, the salts obtained by adding pharmaceutically acceptable acids, such as hydrochloride, hydrobromide, sulphate or bisulphate, phosphate or acid phosphate, acetate, benzoate, succinate, fumarate, maleate, lactate, citrate, tartrate, gluconate, methane sulphonate, benzene sulphonate and paratoluene sulphonate. It is expected that the compounds of formula (I), which do not contain a clear positive or negative charge, are more efficient at crossing the blood-brain barrier.
- A is preferably equal to the group
- R1 is preferably H and R2 is preferably the group CH 2 PhR3,R4,R5 with R3, R4 and R5 being preferably methoxy.
- R1 is preferably the group -CH 2 -CH(cycloalkyl(C 5 -C 6 ))2; m is preferably equal to 0.
- Y is preferably the group (CH 2 ) q -0 and q is 2.
- the compounds of general formula (I) can be prepared using known reactions in the state of the art and can also be prepared with parallel chemistry using a suitable reactor consisting of several reaction tubes in each of which a reaction is set up with various reagents but under the same conditions of temperature and inert atmosphere.
- Diagram A An example of synthesis is given in Diagram A below.
- Step 2 When m is 0, the isocyanate attacks the amine; the solvents which are preferably used have low boiling points and are chlorided like dichloromethane.
- the reaction temperature is between 20 and 40 0 C preferably 25 0 C.
- the reaction time is between 1 and 18 hours, preferably 2 hours.
- the reaction temperature is between 50 and 140 0 C, preferably 120 0 C.
- the reaction time is between 5 and 30 hours, preferably 24 hours. All the reactions are conducted in a stream of inert gas, preferably argon. In each reaction one of the two reagents is present in excess quantities equal to 0.5 mols compared with the defective reagent, the excess reagent is removed by using polystyrene "scavenger" resins.
- the isocyanate is preferably used in excess quantities compared with the amine and/or alcohol, and the aminomethyl polystyrene resin allows the excess to be removed.
- the compounds of formula (I) are also used in the prevention and/or treatment of heart disorders such as CHF (congestive heart failure).
- CHF congestive heart failure
- a further object of the present invention are pharmaceutical compounds containing one or more compounds of formula (I) described first in combination with excipients and/or pharmaceutically acceptable diluents.
- the compounds in question may, together with the compounds of formula (I), contain known active ingredients.
- the pharmaceutical compounds according to the present invention can be adapted for oral, parenteral, rectal, transdermal and intranasal administration.
- the oral form includes capsules, tablets, granules, powders, syrups and elixirs.
- the parenteral forms include solutions or emulsions.
- the dosage of the compounds of the present invention varies according to the type of compound used, the route of administration and the extent to which the disease to be treated has developed. In general an effective dosage is between 0.1 and
- the invention also includes the use of formula (I) compounds for preparing medicaments having hypoglycaemic and anti-obesity action.
- a further aspect of the invention is a process for preparing pharmaceutical compounds characterised by mixing one or more compounds of formula (I) with suitable, stabilising and/or pharmaceutically-acceptable diluents.
- Another object of the present invention is the method for treating a mammal suffering from hyperglycaemia, diabetes, obesity and associated disorders, as reported above, including the administration of a therapeutically-effective quantity of the compound of formula (I).
- Kl is added in catalytic quantities (0.22 g) and bromoethanol (0.056 g; 0.45 mmols). The reaction is left at 40 0 C for 24 hours under magnetic stirring. The reaction mixture is then filtered and evaporated under reduced pressure.
- the phenylethyl isocyanate (0.026 g; 0.179 mmols) is added to the intermediate 1- (2-hydroxyethyl)-4-(2,3,4 trimethoxybenzyl)piperazine prepared as described above (0.037 g; 0.119 mmols) dissolved in 2.5 ml of toluene.
- the reaction mixture is left at 130 0 C at reflux for 24 hours under continuous magnetic stirring.
- the raw reaction product is purified with sulphuryl chloride polystyrene resin (0.032 g; capacity 1.52 mmols/g) in the presence of triethylamine (4.9 mg, 5 ⁇ l_, 0.048 mmols).
- the reaction was left for one hour at room temperature under slow magnetic stirring.
- the aminomethyl resin (0.056 g; 2.7 mmols/g) was then added to the filtrate and the mixture left for 2 hours at room temperature under slow magnetic stirring.
- Example 4 Synthesis of 4-benzyl-N-(4-fluorobenzyl)-1-carboxyamide-piperazine ST3344
- the compound of example 4 was prepared as described in example 3 from 4- benzyl piperazine and 4-fluorobenzyl isocyanate to give 0.048 g of product (yield 79%)
- Example 7 Synthesis of 4-benzoyl-N-(2-phenylethyl)-1 -carboxamide-piperazine ST3341
- the compound of example 7 was prepared as described in example 3 from A- benzoyl piperazine and 2- phenylethyl isocyanate to give 0.040 g of product (yield 75.2%)
- the compound of example 11 was prepared as described in example 3 from 2- (2,2-dicycloesylethyl)piperidine and 4-fluorophenyl isocyanate to give 0.035 g of product (yield 91 %)
- the compound of example 17 was prepared as described in example 3 from 2- (2,2-dicycloesylethyl)piperidine and 4-methoxybenzyl isocyanate to give 0.025g of product (yield 34%).
- the compound of example 20 was prepared as described in example 3 from A-
- the compound of example 22 was prepared as described in example 3 from A- (bis(4-fluorophenyl)methyl)piperazine and 4-chlorophenyl isocyanate to give 0.025g of product (yield 34%)
- the compound of example 23 was prepared as described in example 3 from A- (bis(4-fluorophenyl)methyl)piperazine and 4-methoxybenzyl isocyanate to give 0.039g of product (yield 52%)
- the compound of example 24 was prepared as described in example 3 from A- (1 ,3-benzodioxol-5-methyl)piperazine and 2-phenylethyl isocyanate to give 0.053g of product (yield 86%)
- the compound of example 25 was prepared as described in example 3 from A- (1 ,3-benzodioxol-5-methyl)piperazine and 4-ethylphenyl isocyanate to give 0.053g of product (yield 86%)
- the compound of example 26 was prepared as described in example 3 from A- (1 ,3-benzodioxol-5-methyl)piperazine and 4-heptyloxyphenyl isocyanate to give 0.062g of product (yield 82%)
- the compound of example 28 was prepared as described in example 3 from A- (1 ,3-benzodioxol-5-methyl)piperazine and 4-chlorophenyl isocyanate to give 0.052g of product (yield 83%)
- the compound of example 30 was prepared as described in example 3 from A- (2,3,4-trimethoxybenzyl)piperazine and 4-heptyloxyphenyl isocyanate to give 0.082g of product (yield 75%)
- the compound of example 31 was prepared as described in example 3 from A- (2,3,4-trimethoxybenzyl)piperazine and 2-phenylethyl isocyanate to give 0.030 g of product (yield 90%)
- the compound of example 34 was prepared as described in example 3 from A- (2,3,4-trimethoxybenzyl)piperazine and 4-methoxybenzyl isocyanate to give 0.033g of product (yield 85%) ESI-MS m/z 430 [M+H] ⁇ 452 [M+Na] + .
- Example 35 Synthesis of 4-(2,3,4-trimethoxybenzyl)-N-(4-chlorophenyl)-1 -carboxyamide- piperazine ST3414
- the compound of example 36 was prepared as described in example 3 from A- (2,3,4-trimethoxybenzyl)piperazine and 4-metylthiophenyl isocyanate to give 0.040 g of product (yield 93 %)
- the compound of example 38 was prepared as described in example 3 from A-
- the compound of example 39 was prepared as described in example 3 from A- (2,3,4-trimethoxybenzyl)piperazine and 2,4-(dichlorophenyl)isocyanate to give
- the compound of example 40 was prepared as described in example 3 from 2- (2,2-dicycloesylethyl)piperidine and 4-methylthiophenyl isocyanate to give 0.049 g of product (yield 98%)
- the compound was prepared as described in example 3 from 1-(2-aminoetyl)-4- (2,3,4-trymethoxybenzyil)piperazine prepared as described in example 41 and 2,4 dichlorophenylisocyanate.
- the raw product obtained was purified by SPE (SCX) to give 0.028 g of product (yield of 85%).
- Test 1 Evaluation of the inhibitory activity on CPT
- the inhibition of CPT has been evaluated on fresh mitochondrial preparations obtained from the liver or heart of the normally fed Fischer rat; the mitochondria taken from the liver or heart are suspended in 75 mM sucrose, EGTA 1 mM, pH 7.5. 100 ⁇ l of a mitochondrial suspension, containing 50 ⁇ M of [ 14 C] palmitoyl-CoA (spec. act. 10000 dpm/mole) and 10 mM of L-carnitine, are incubated at 37 0 C in the presence of scalar concentrations (0-3 mM) of the product under examination. Reaction time: 1 minute. The IC50 is then evaluated.
- Test 2 Evaluation of the production of ⁇ -hvdroxybutyrate stimulated by oleate The synthesis of ⁇ -hydroxybutyrate is an indicator of the activity of CPT. In fact the production of ketone bodies, end-products of mitochondrial beta-oxidation, is linked to the activity of CPT.
- hepatocytes obtained according to the technique described by Venerando R. et al. (1994) Am. J. Physiol. 266: C455-C461] are used.
- the hepatocytes are incubated at 37°C in KRB bicarbonate buffer at pH 7.4, 6 mM glucose, 1 % BSA in O2/CO2 95/5 % atmosphere at a concentration of 2.5 x 10 6 cells/ml.
- the first series of samples is taken (T 0 mm ) and the oleate added (1 final mM in KRB + BSA 1.4%). After 20 mins the second sample is taken
- Test 3 ⁇ -hydroxybutyrate in the serum of treated rats
- Normally-fed Fischer rats is left to fast for 24 hours and is then treated with the compounds under examination. One hour after the treatment the animals is sacrificed and the serum concentrations of ⁇ -hydroxybutyrate are evaluated.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne une nouvelle classe de composés à activité inhibitrice vis-à-vis de la carnitine palmitoyltransférase (CPT) dans le système nerveux central (SNC), lesdits composés étant dérivés de la trimétazidine et de la perhexiline, et étant de préférence sélectifs vis-à-vis de la forme hépatique de CPT1 (CPT1L). La présente invention concerne également les composés pharmaceutiques contenant au moins un nouveau composé selon l'invention, ainsi que leur utilisation thérapeutique dans le traitement prophylactique et/ou thérapeutique de l'obésité, de l'hyperglycémie, du diabète et des troubles associés, par exemple la rétinopathie diabétique, la neuropathie diabétique et les troubles cardio-vasculaires. Les composés selon la présente invention sont également employés dans le traitement prophylactique et/ou thérapeutique de troubles cardiaques tels que l'insuffisance cardiaque congestive (ICC).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000090A ITRM20060090A1 (it) | 2006-02-22 | 2006-02-22 | Nuovi composti inibitori cpt a livello del snc come farmaci antidiabetici e o antiobesita |
ITRM2006A000090 | 2006-02-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007096251A1 true WO2007096251A1 (fr) | 2007-08-30 |
Family
ID=37903503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2007/051197 WO2007096251A1 (fr) | 2006-02-22 | 2007-02-08 | Inhibiteurs de cpt dans le système nerveux central en tant que médicaments antidiabétiques et/ou anti-obésité |
Country Status (2)
Country | Link |
---|---|
IT (1) | ITRM20060090A1 (fr) |
WO (1) | WO2007096251A1 (fr) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008122787A1 (fr) * | 2007-04-05 | 2008-10-16 | Evotec Ag | Composés de pipérazine pour l'inhibition de prostaglandine synthase d hématopoïétique |
WO2009021740A2 (fr) | 2007-08-15 | 2009-02-19 | Sanofis-Aventis | Nouvelles tétrahydronaphtalines substituées, leurs procédés de préparation et leur utilisation comme médicaments |
WO2010068453A1 (fr) | 2008-11-25 | 2010-06-17 | Janssen Pharmaceutica Nv | Modulateurs d'urée substitués par hétéroaryle d'amide d'acide gras hydrolase |
WO2010141809A1 (fr) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Modulateurs heterocycliques a base d'uree a substitution aryle de l'hydrolase des amides d'acides gras (faah) |
WO2010141817A1 (fr) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Modulateurs d'amide d'acide gras hydrolase de type diamine urée spirocyclique substituée par un groupe hétéroaryle |
WO2011157827A1 (fr) | 2010-06-18 | 2011-12-22 | Sanofi | Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases |
WO2012120054A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
WO2012120056A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
WO2012120052A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation |
WO2012120053A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation |
WO2012120055A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
EP2567959A1 (fr) | 2011-09-12 | 2013-03-13 | Sanofi | Dérivés d'amide d'acide 6-(4-Hydroxy-phényl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs |
US8598356B2 (en) | 2008-11-25 | 2013-12-03 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
WO2014036603A1 (fr) * | 2012-09-05 | 2014-03-13 | Adelaide Research & Innovation Pty Ltd | Utilisations de (-)-perhexiline |
US8940745B2 (en) | 2010-05-03 | 2015-01-27 | Janssen Pharmaceutica Nv | Modulators of fatty acid amide hydrolase |
WO2015131231A1 (fr) * | 2014-03-03 | 2015-09-11 | Adelaide Research & Innovation Pty Ltd | Procédés d'utilisation de (-)-perhexiline |
US9169224B2 (en) | 2004-12-30 | 2015-10-27 | Janssen Pharmaceutica Nv | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase |
US9393221B2 (en) | 2011-07-20 | 2016-07-19 | The General Hospital Corporation | Methods and compounds for reducing intracellular lipid storage |
US9457017B2 (en) | 2007-11-23 | 2016-10-04 | Heart Metabolics Limited | Treatment of heart failure |
WO2017031330A1 (fr) * | 2015-08-20 | 2017-02-23 | The Regents Of The University Of Californa | Procédés de réduction de la protéotoxicité |
JP2019509338A (ja) * | 2016-02-23 | 2019-04-04 | セルビシオ アンダルーサ デ サルー | 治療活性が増加した抗ウイルス剤としてのピペラジン誘導体 |
US10556013B2 (en) | 2017-06-20 | 2020-02-11 | Imbria Pharmaceuticals, Inc. | Compositions and methods for increasing efficiency of cardiac metabolism |
WO2020081361A1 (fr) | 2018-10-17 | 2020-04-23 | Imbria Pharmaceuticals, Inc. | Procédés de traitement de maladies rhumatismales à l'aide de composés à base de trimétazidine |
US20220249463A1 (en) * | 2019-05-31 | 2022-08-11 | Imbria Pharmaceuticals, Inc. | Methods of altering cardiac remodeling using compounds that promote glucose oxidation |
US11530184B2 (en) | 2020-06-30 | 2022-12-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
US11780811B2 (en) | 2020-06-30 | 2023-10-10 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
US11883396B2 (en) | 2021-05-03 | 2024-01-30 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3721674A (en) * | 1970-03-02 | 1973-03-20 | Upjohn Co | Piperazinyl ethyl carbamates |
US3823006A (en) * | 1970-10-30 | 1974-07-09 | Bayer Ag | Method for selective weed control in beets |
US4122090A (en) * | 1976-06-05 | 1978-10-24 | Basf Aktiengesellschaft | Cyclic esters of 3,4-dihydroxy-thiophene-1,1-dioxide compounds and 3,4-dihydroxy-cyclopentadienone compounds |
EP0129207A2 (fr) * | 1983-06-16 | 1984-12-27 | Boehringer Ingelheim Pharmaceuticals Inc. | Phénylalkyl(pipérazinyl ou homopipérazinyl)-propyl-(urées ou thiourées) substituées |
WO1997026252A1 (fr) * | 1996-01-19 | 1997-07-24 | Fmc Corporation | Piperazines insecticides n-heterocyclylalkyle- ou n-[(polycyclyle)-alkyle]-n'-substituees |
WO1997042230A1 (fr) * | 1996-05-03 | 1997-11-13 | Warner-Lambert Company | Purification rapide par reactifs de refroidissement brusque supportes par des polymeres |
WO2006074025A1 (fr) * | 2004-12-30 | 2006-07-13 | Janssen Pharmaceutica N.V. | Urees piperazinyle et piperidinyle en tant que modulateurs de l’amide hydrolase d’acides gras |
-
2006
- 2006-02-22 IT IT000090A patent/ITRM20060090A1/it unknown
-
2007
- 2007-02-08 WO PCT/EP2007/051197 patent/WO2007096251A1/fr active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3721674A (en) * | 1970-03-02 | 1973-03-20 | Upjohn Co | Piperazinyl ethyl carbamates |
US3823006A (en) * | 1970-10-30 | 1974-07-09 | Bayer Ag | Method for selective weed control in beets |
US4122090A (en) * | 1976-06-05 | 1978-10-24 | Basf Aktiengesellschaft | Cyclic esters of 3,4-dihydroxy-thiophene-1,1-dioxide compounds and 3,4-dihydroxy-cyclopentadienone compounds |
EP0129207A2 (fr) * | 1983-06-16 | 1984-12-27 | Boehringer Ingelheim Pharmaceuticals Inc. | Phénylalkyl(pipérazinyl ou homopipérazinyl)-propyl-(urées ou thiourées) substituées |
WO1997026252A1 (fr) * | 1996-01-19 | 1997-07-24 | Fmc Corporation | Piperazines insecticides n-heterocyclylalkyle- ou n-[(polycyclyle)-alkyle]-n'-substituees |
WO1997042230A1 (fr) * | 1996-05-03 | 1997-11-13 | Warner-Lambert Company | Purification rapide par reactifs de refroidissement brusque supportes par des polymeres |
WO2006074025A1 (fr) * | 2004-12-30 | 2006-07-13 | Janssen Pharmaceutica N.V. | Urees piperazinyle et piperidinyle en tant que modulateurs de l’amide hydrolase d’acides gras |
Non-Patent Citations (9)
Title |
---|
"AKos Screening Library", 7 January 1006, AKOS-CONSULTING AND SOLUTIONS GMBH, BASEL, CH * |
CHO J K; WHITE P D; KLUTE W; DEAN T W; BRADLEY M: "Self-indicating amine scavenger resins", CHEMICAL COMMUNICATIONS, 2004, pages 502 - 503, XP002429172 * |
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SILVERMAN, IAN R. ET AL: "Preparation of N-heterocyclylalkyl- or N-[(polycyclyl)-alkyl]-N'- substituted piperazines as insecticides.", XP002429176, retrieved from STN Database accession no. 1997:499179 * |
DATABASE CHEMCATS CHEMICAL ABSTRACT SERVICES, COLUMBUS, OHOI, US; XP002429175 * |
EIDEN, FRITZ ET AL: "Analysis of calcium antagonists. III. Verapamil, diltiazem, and perhexiline (1)", PHARMAZEUTISCHE ZEITUNG , 129(12), 678-85 CODEN: PHZIAP; ISSN: 0031-7136, 1984, XP001245693 * |
GIANNESSI F: "CARNITINE PALMITOYLTRANSFERASE INHIBITORS IN THE MANAGEMENT OF TYPE 2 DIABETES: AN OLD PROMISE TO BE MAINTAINED", DRUGS OF THE FUTURE, BARCELONA, ES, vol. 28, no. 4, 1 April 2003 (2003-04-01), pages 371 - 381, XP009047902, ISSN: 0377-8282 * |
LEE, S-H; MATSUSHITA H; CLAPHAM B; JANDA K D: "The direct conversion of carbamates tu ureas using aluminium hydrides", TETRAHEDRON, vol. 60, 2004, pages 3439 - 3443, XP002429171 * |
MINH D N ET AL: "Study of local anaesthetics. Part 98(3): Preparation and local anaesthetic activity of 4-alkylpiperazinoethyl esters of o-heptyloxyphenylcarbamic acid.", DIE PHARMAZIE FEB 1992, vol. 47, no. 2, February 1992 (1992-02-01), pages 94 - 96, XP001249083, ISSN: 0031-7144 * |
SCHWEIM H G ET AL: "N-ACYL- UND N-ARYL-N'-ALKYLIDENHARNSTOFFE ALS VORSTUFEN VON ISOCYANATEN ODER ACYLISOCYANATEN N-ACYL- AND N-ARYL-N'-AKYLIDENUREAS AS PRECURSORS OF ISOCYANATES ORACYLISOCYANATES", ARCHIV DER PHARMAZIE, VCH VERLAGSGESELLSCHAFT MBH, WEINHEIM, DE, vol. 320, no. 9, 1987, pages 844 - 850, XP001002079, ISSN: 0365-6233 * |
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9169224B2 (en) | 2004-12-30 | 2015-10-27 | Janssen Pharmaceutica Nv | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase |
WO2008122787A1 (fr) * | 2007-04-05 | 2008-10-16 | Evotec Ag | Composés de pipérazine pour l'inhibition de prostaglandine synthase d hématopoïétique |
WO2009021740A2 (fr) | 2007-08-15 | 2009-02-19 | Sanofis-Aventis | Nouvelles tétrahydronaphtalines substituées, leurs procédés de préparation et leur utilisation comme médicaments |
US9468634B2 (en) | 2007-11-23 | 2016-10-18 | Heart Metabolics Limited | Treatment of heart failure |
US9457017B2 (en) | 2007-11-23 | 2016-10-04 | Heart Metabolics Limited | Treatment of heart failure |
US8877769B2 (en) | 2008-11-25 | 2014-11-04 | Janseen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
WO2010068453A1 (fr) | 2008-11-25 | 2010-06-17 | Janssen Pharmaceutica Nv | Modulateurs d'urée substitués par hétéroaryle d'amide d'acide gras hydrolase |
US8598356B2 (en) | 2008-11-25 | 2013-12-03 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
US8461159B2 (en) | 2008-11-25 | 2013-06-11 | Jannsen Pharmaceutica BV | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
WO2010141809A1 (fr) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Modulateurs heterocycliques a base d'uree a substitution aryle de l'hydrolase des amides d'acides gras (faah) |
US8901111B2 (en) | 2009-06-05 | 2014-12-02 | Janssen Pharmaceutica Nv | Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase |
WO2010141817A1 (fr) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Modulateurs d'amide d'acide gras hydrolase de type diamine urée spirocyclique substituée par un groupe hétéroaryle |
US9688664B2 (en) | 2010-05-03 | 2017-06-27 | Janssen Pharmaceutica Nv | Modulators of fatty acid amide hydrolase |
US8940745B2 (en) | 2010-05-03 | 2015-01-27 | Janssen Pharmaceutica Nv | Modulators of fatty acid amide hydrolase |
WO2011157827A1 (fr) | 2010-06-18 | 2011-12-22 | Sanofi | Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases |
WO2012120055A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
WO2012120053A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation |
WO2012120052A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation |
WO2012120056A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
WO2012120054A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
US9393221B2 (en) | 2011-07-20 | 2016-07-19 | The General Hospital Corporation | Methods and compounds for reducing intracellular lipid storage |
EP2567959A1 (fr) | 2011-09-12 | 2013-03-13 | Sanofi | Dérivés d'amide d'acide 6-(4-Hydroxy-phényl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs |
WO2014036603A1 (fr) * | 2012-09-05 | 2014-03-13 | Adelaide Research & Innovation Pty Ltd | Utilisations de (-)-perhexiline |
WO2015131231A1 (fr) * | 2014-03-03 | 2015-09-11 | Adelaide Research & Innovation Pty Ltd | Procédés d'utilisation de (-)-perhexiline |
WO2017031330A1 (fr) * | 2015-08-20 | 2017-02-23 | The Regents Of The University Of Californa | Procédés de réduction de la protéotoxicité |
JP2019509338A (ja) * | 2016-02-23 | 2019-04-04 | セルビシオ アンダルーサ デ サルー | 治療活性が増加した抗ウイルス剤としてのピペラジン誘導体 |
US10953102B2 (en) | 2017-06-20 | 2021-03-23 | Imbria Pharmaceuticals, Inc. | Compositions and methods for increasing efficiency of cardiac metabolism |
US11844840B2 (en) | 2017-06-20 | 2023-12-19 | Imbria Pharmaceuticals, Inc. | Compositions and methods for increasing efficiency of cardiac metabolism |
US10918728B2 (en) | 2017-06-20 | 2021-02-16 | Imbria Pharmaceuticals, Inc. | Compositions and methods for increasing efficiency of cardiac metabolism |
US10556013B2 (en) | 2017-06-20 | 2020-02-11 | Imbria Pharmaceuticals, Inc. | Compositions and methods for increasing efficiency of cardiac metabolism |
US11376330B2 (en) | 2017-06-20 | 2022-07-05 | Imbria Pharmaceuticals, Inc. | Compositions and methods for increasing efficiency of cardiac metabolism |
EP3866794A4 (fr) * | 2018-10-17 | 2022-07-20 | Imbria Pharmaceuticals, Inc. | Procédés de traitement de maladies rhumatismales à l'aide de composés à base de trimétazidine |
WO2020081361A1 (fr) | 2018-10-17 | 2020-04-23 | Imbria Pharmaceuticals, Inc. | Procédés de traitement de maladies rhumatismales à l'aide de composés à base de trimétazidine |
US20220249463A1 (en) * | 2019-05-31 | 2022-08-11 | Imbria Pharmaceuticals, Inc. | Methods of altering cardiac remodeling using compounds that promote glucose oxidation |
US11530184B2 (en) | 2020-06-30 | 2022-12-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
US11746090B2 (en) | 2020-06-30 | 2023-09-05 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4- trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
US11780811B2 (en) | 2020-06-30 | 2023-10-10 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
US12065410B2 (en) | 2020-06-30 | 2024-08-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
US12110275B2 (en) | 2020-06-30 | 2024-10-08 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl] piperazin-1-yl]ethyl pyridine-3-carboxylate |
US11883396B2 (en) | 2021-05-03 | 2024-01-30 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
Also Published As
Publication number | Publication date |
---|---|
ITRM20060090A1 (it) | 2007-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007096251A1 (fr) | Inhibiteurs de cpt dans le système nerveux central en tant que médicaments antidiabétiques et/ou anti-obésité | |
Titus et al. | Resolution and absolute configuration of an ergoline-related dopamine agonist, trans-4, 4a, 5, 6, 7, 8, 8a, 9-octahydro-5-propyl-1H (or 2H)-pyrazolo [3, 4-g] quinoline | |
US7531685B2 (en) | Deuterium-enriched oxybutynin | |
EP1140836B1 (fr) | Composes amide | |
EP0343961A2 (fr) | Aryl- et hétéroaryl pipérazinyl carboxamides avec activité sur le système nerveux central | |
EP0581167B1 (fr) | Dérivés de arylglycinamide, leur procédé de préparation et leur usage pour le traitement de la dysurie | |
SK20199A3 (en) | Ether muscarinic antagonists | |
SK118794A3 (en) | 4(4'-piperidinyl or 3'- pyrrolidinyl) substitutes imidazoles as h3-receptor | |
Larson et al. | Stereochemical studies on medicinal agents. 12. Distinction of enantiotopic groups in the interaction of 1-methyl-4-phenyl-4-propionoxypiperidine with analgetic receptors | |
JPH04217663A (ja) | 4−アミノメチルピペリジン誘導体 | |
DE60015732T2 (de) | Amidverbindungen zur stärkung der cholinergischen wirkung | |
US5965734A (en) | Processes and intermediates for preparing 2-substituted piperidine stereoisomers | |
US5106849A (en) | Use of aryl- and heteroaryl piperazinyl carboxamides in the treatment of various central nervous system disorders | |
Böck et al. | N‐Substituted Nipecotic Acids as (S)‐SNAP‐5114 Analogues with Modified Lipophilic Domains | |
US5482940A (en) | Use of aryl- and heteroaryl piperazinyl carboxamides in the treatment of various central nervous system disorders | |
WO2006092204A1 (fr) | Derives de l’acide aminobutanoique inhibant la cpt | |
CN103787954B (zh) | 一类氟取代的环状胺类化合物及其制备方法、药物组合物和用途 | |
JP3041834B2 (ja) | N―アミノアルキル―2―アントラキノンカルボキサミド;ドーパミンレセプターサブタイプに特異的な新しい配位子 | |
FI91398C (fi) | Menetelmä terapeuttisesti käyttökelpoisten sulfonanilidien valmistamiseksi | |
JP2008500985A (ja) | ブチリルコリンエステラーゼ選択的阻害剤 | |
US5278160A (en) | Use of aryl- and heteroaryl piperazinyl carboxamides in the treatment of various central nervous system disorders | |
US5639775A (en) | 4-[4'-piperodinyl or 3'-pirrolidinyl] substituted imidazoles as H3 -receptor antagonists and therapeutic uses thereof | |
JP3091233B2 (ja) | 新規n―アミノアルキル―1―ビフェニレンイル―2―カルボキサミド、新しいドーパミンレセプター・サブタイプ特定リガンド | |
US4906622A (en) | Optically active 2-chloro-12-(3-dimethylamino-2-methyl-propyl)-12H-dibenzo[d.g] [1,3,6] dioxazocines and a process for the preparation thereof | |
EP0522914A1 (fr) | Dérivés de 2-pipéridinylpyrimidine-4-carboxamide, leur préparation et leur application en thérapeutique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07704450 Country of ref document: EP Kind code of ref document: A1 |